---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-009273"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T02:58:23.404000+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Interpace Q1 revenue $11.5M (+13% YoY); guides FY2025 ~$38M

## Summary
- Net revenue $11.5M (+13% YoY); income from continuing ops $1.8M vs $0.8M.
- Thyroid revenue $8.0M (+19% YoY) to record; test volume up 16%.
- Cash collections $11.3M (+10% YoY) to record; adjusted EBITDA $2.1M vs $1.2M.
- Initiates FY2025 revenue guidance of approx. $38M despite PancraGEN loss after May 2.
- Gross profit margin improved to 64% from 62%.

## SEC filing metadata
- accession: 0001641172-25-009273
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000164117225009273/0001641172-25-009273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000164117225009273/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-009273
- JSON: https://secwatch.observer/filing/0001641172-25-009273.json
- Plain text: https://secwatch.observer/filing/0001641172-25-009273.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.